A detailed history of Erste Asset Management Gmb H transactions in Exelixis, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 74,500 shares of EXEL stock, worth $2.47 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
74,500
Holding current value
$2.47 Million
% of portfolio
0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $1.64 Million - $2.06 Million
74,500 New
74,500 $1.93 Billion
Q2 2022

Nov 26, 2024

SELL
$17.44 - $23.16 $1.9 Million - $2.53 Million
-109,200 Reduced 59.44%
74,500 $1.55 Billion
Q3 2021

Nov 22, 2024

SELL
$16.3 - $21.14 $268,950 - $348,810
-16,500 Reduced 18.13%
74,500 $1.54 Billion
Q4 2020

Nov 22, 2024

SELL
$18.39 - $24.8 $1.25 Million - $1.69 Million
-68,000 Reduced 42.77%
91,000 $1.83 Billion
Q3 2020

Nov 22, 2024

BUY
$20.67 - $26.94 $1.75 Million - $2.28 Million
84,500 Added 113.42%
159,000 $3.9 Billion
Q1 2020

Nov 22, 2024

SELL
$14.46 - $21.8 $245,820 - $370,600
-17,000 Reduced 9.1%
169,800 $3.02 Billion
Q4 2019

Nov 22, 2024

BUY
$15.15 - $18.89 $1.7 Million - $2.12 Million
112,300 Added 150.74%
186,800 $3.39 Billion
Q2 2019

Nov 22, 2024

BUY
$18.93 - $24.75 $200,658 - $262,350
10,600 Added 6.02%
186,800 $4.01 Billion
Q1 2019

Nov 22, 2024

BUY
$19.6 - $24.76 $1.99 Million - $2.52 Million
101,700 Added 136.51%
176,200 $4.16 Billion
Q4 2018

Nov 26, 2024

BUY
$13.65 - $21.8 $1.49 Million - $2.38 Million
109,200 Added 146.58%
183,700 $3.54 Billion

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.